ArcherDX Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boulder, CO USA
Total Funding:$35M
Industry:Biotech
Founded:2013
Lead Investor(s):Boulder Ventures, PBM Capital Group, LLC
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • ArcherDX's estimated annual revenue is currently $49.4M per year.
  • ArcherDX received $35.0M in venture funding in March 2018.
  • ArcherDX's estimated revenue per employee is $155,000
  • ArcherDX's total funding is $35M.

Employee Data

  • ArcherDX has 319 Employees.
  • ArcherDX grew their employee count by 83% last year.
  • ArcherDX currently has 16 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
MBio Diagnostic...
$5.4M3535%N/A
CereScan
$4.3M28N/AN/A
ARCA biopharma
N/A21N/AN/A
Flagship Biosci...
$6.4M41N/AN/A
GlobeImmune
$5.4M350%N/A
Strand Life Sci...
$54.9M354N/AN/A
Isolate Extract...
$6.8M4433%N/A
Biodesix
$19.1M1481%N/A
Cerecin, previo...
N/A35N/AN/A
Horizon Ag-Prod...
$7.3M47N/AN/A
Missing a competitor? Contribute!?
Submit

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

319

Number of Employees

$49.4M

Revenue (est)

16

Current Jobs

83%

Employee Growth %

$35M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Kyle LefkoffMember Board of Directors
Matt FranklinChief Business OfficerEmail Available
Pamela BalsleyTradeshow ManagerEmail Available
Garry DallmannProtein Development And Production ManagerEmail Available
Randall EvansVice President, Diagnostics And Clinical DevelopmentEmail Available
Ryan ShayMarketing ManagerEmail Available
Holly Baden-TillsonFAS Manager, US
Rhonda SchisslerClincial Data Manager IIEmail Available
Andrea FlynnVice President, Investor Relations & Corporate CommunicationsEmail Available
Paul LatimerAssociate Alliance And Revenue ManagerEmail Available

ArcherDX News

09/08/2019 - Immune Repertoire Sequencing Market – Survey On Potential Players 2028 | Atreca, Inc., ArcherDX, Inc.

For example, Archer Immunoverse B Cell Receptor (BCR) was launched by ArcherDX, Inc in 2017 to examine human B cell repertoire.

05/15/2019 - ArcherDX Announces Close of $60M Financing to Advance ...

BOULDER, Colo., May 15, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...

03/05/2019 - ArcherDX Announces Expansion of Executive Leadership ...

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...

ArcherDX Funding

DateAmountRoundLead InvestorsReference
2018-03-21$35.0MABoulder Ventures, Ltd.Article

ArcherDX Acquisitions

DateCompany NameAmountNotesReference
2019-01-31Baby Genes, IncArticle